Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05704361 · ClinicalTrials.gov registry record · Phase 1

A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis

A Phase 1 study of Multiple Sclerosis, sponsored by Hoffmann-La Roche.

Recruiting
Registry status
Phase 1
Development phase
129
Enrollment target
20
Study locations

NCT05704361 is a Phase 1 study of Multiple Sclerosis that is actively recruiting participants, run by Hoffmann-La Roche. The registered enrollment target is 129 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05704361, a Phase 1 study of Multiple Sclerosis, is actively recruiting participants, sponsored by Hoffmann-La Roche.

RECRUITING
Registry status
Phase 1
Development phase
129 participants
Enrollment target
20
Study locations

Study Summary

The primary purpose of the study is to evaluate the safety and tolerability of a single-ascending intravenous (IV) dose (Part 1), a single-ascending subcutaneous (SC) dose (Part 2), and multiple ascending SC doses (Part 3) of RO7121932 in participants with multiple sclerosis (MS).

Conditions Studied

Multiple Sclerosis

Interventions

  • DRUG RO7121932 IV
  • DRUG RO7121932 SC

Study Locations (20)

Other

  • Cliniques Universitaires St-Luc - Brussels
  • UZ Gent - Ghent
  • Universitätsklinikum "Carl Gustav Carus" - Dresden
  • Universitätsmedizin Göttingen Georg-August-Universität - Göttingen
  • Klinikum rechts der Isar der TU Muenchen - München
  • Universitätsklinikum Münster Klinik u. Poliklinik f. Neurologie - Münster
  • Universitätsklinikum Tübingen, Zentrum für Neurologie - Tübingen
  • Universitätsklinikum Ulm - Ulm
  • Hadassah University Hospital - Ein Kerem - Jerusalem
  • Tel Aviv Sourasky Medical Center - Tel Aviv
  • ARENSIA Exploratory Medicine Phase I, PMSI Republican Clinical Hospital - Chisinau
  • Uniwersyteckie Centrum Kliniczne - Gda?sk

Lombardy

  • IRCCS Ospedale San Raffaele - Milan
  • Fond. Istituto Neurologico C.Besta - Milan

California

  • Stanford University Medical Center - Stanford

Connecticut

  • Yale University Multiple Sclerosis Center - New Haven

Florida

  • University of South Florida - Tampa

Massachusetts

  • University of Massachusetts Medical School - Worcester

Ohio

  • UC Health, LLC. - Cincinnati

Quebec

  • Montreal Neurological Institute and Hospital - Montreal

Trial Details

FieldValue
Enrollment Target 129 participants
Start Date 2021-08-11
Est. Completion 2027-07-08
Phase Phase 1

Sponsor

Hoffmann-La Roche

909 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05704361

The ClinicalTrials.gov registry entry for NCT05704361 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 129 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (78% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which RO7121932 IV is the first listed.

NCT05704361 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Other, Lombardy, California.

Frequently Asked Questions

What is clinical trial NCT05704361 about?

NCT05704361 is a clinical study titled "A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis". The primary purpose of the study is to evaluate the safety and tolerability of a single-ascending intravenous (IV) dose (Part 1), a single-ascending subcutaneous (SC) dose (Part 2), and multiple ascending SC doses (Part 3) of RO7121932 in participants with multiple sclerosis (MS).

What is the current status of trial NCT05704361?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 129 participants. The study started on 2021-08-11. Estimated completion is 2027-07-08.

What conditions does trial NCT05704361 study?

This clinical trial studies the following conditions: Multiple Sclerosis.

What interventions are being tested in trial NCT05704361?

The interventions under investigation include: RO7121932 IV (DRUG), RO7121932 SC (DRUG).

Who is sponsoring clinical trial NCT05704361?

This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05704361 being conducted?

This trial has 20 study locations across California, Connecticut, Florida, Massachusetts, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Sclerosis

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.